TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum

PR Newswire


EDINBURGH, Scotland 
, Feb. 20, 2025 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) , a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its CEO will join the Cancer Progress Panel discussion on February 27th at 1:10 pm CET at the 18th Annual European Life Sciences CEO Forum, which will include HealthTech topics such as AI, convergence, and diagnostics.

The forum will take place on the 26th – 27th of February 2025 at the Hilton Zurich Airport Hotel. The main programme for the 18th Annual ELSF will feature more than 12 hours of high-level keynotes and panel discussions. 

Additionally, there will be a global company showcase of 50+ presentations by established public, private, emerging, and seed companies, offering innovative solutions and seeking investment and partnering opportunities. For more information about the 18th Annual European Life Sciences CEO Forum, please click here.

About TC BioPharm (Holdings) PLC

TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.

TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line – Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using the Company’s proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.

Forward-Looking Statements for TC BioPharm

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company’s intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management’s current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company’s Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company’s beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-ceo-bryan-kobel-to-participate-on-cancer-progress-panel-at-18th-annual-european-life-sciences-ceo-forum-302380543.html

SOURCE TC BioPharm

SOBRsafe and Orbiit Announce Partnership to Enhance Alcohol Recovery Through AI and Wearable Technology

PR Newswire


DENVER
, Feb. 20, 2025 /PRNewswire/ — SOBR Safe, Inc. (NASDAQ:SOBR) (“SOBRsafe”), the leader in next-generation alcohol detection technology, and Orbiit, an AI-driven alcohol recovery platform, are proud to announce their first strategic AI partnership, one that will revolutionize the way individuals manage their alcohol use and sobriety. This collaboration represents both a significant commercial development for SOBRsafe, and a major step forward in recovery support – providing individuals with a non-judgmental, accessible and data-driven path to sobriety.

SOBRsafe and Orbiit partner to revolutionize alcohol recovery with AI and wearable technology.

According to AmericanAddictionCenters.org, over 28 million people in the U.S. suffered from Alcohol Use Disorder (AUD) in 2023, yet only 15.6% received treatment1. Recognizing the gap in treatment options, the two companies have identified a critical demand for accessible and innovative recovery solutions. This partnership addresses that need by pairing SOBRsafe’s transformational transdermal alcohol detection wristband with Orbiit’s AI-powered engagement platform, offering a data-driven approach to behavioral modification and enhancing recovery outcomes.

“We are inspired to partner with Orbiit on our shared mission to introduce innovative solutions to individuals on their sobriety journey,” said David Gandini, CEO of SOBRsafe. “In addition to the continuous transdermal alcohol detection, real-time alerts and GPS tracking we already offer with our discrete SOBRsure band, SOBRsure users who engage with Orbiit’s platform will now have access to 24/7 AI support.”

“Human behavior is deeply shaped by habit formation and social reinforcement,” said Dr. Edward Valentin, Ph.D, LCSW MAC, a staff neuroscientist at Emory University and research and development consultant for Orbiit. “Integrating wearables like the SOBRsure band with real-time monitoring with Orbiit’s daily interventions aligns with well-established behavioral science and affective neuroscience principles. By leveraging classical conditioning and cognitive reinforcement, this partnership has the potential to enhance accountability, motivation and long-term recovery success.”

The new partnership features three key components:

  • SOBRsure™ Band – SOBRsafe’s wearable device provides passive, transdermal (touch-based) alcohol detection and serves as a constant, visual reminder of an individual’s sobriety commitment
  • AI-Powered Orbie – A sophisticated chatbot and support system that offers 24/7 engagement, personalized interventions and structured micro-courses designed to reinforce recovery habits
  • SMS Accountability Messaging – Strategically timed messages every day keep users engaged, providing encouragement and actionable insights while seamlessly integrating into daily life

The Orbiit Recovery Program is a six-month initiative priced at $3,995, which includes the SOBRsure band and full access to Orbiit’s AI-driven platform. Orbiit is accessible online and via text message, while SOBRsure band insights are available through the SOBRsafe app. Future integrations could bring an even more seamless experience, allowing users to view their SOBRsure data directly within the Orbiit platform.

By merging AI and wearable technology, SOBRsafe and Orbiit are setting a new standard for alcohol recovery solutions. For more information about the companies and program availability, please visit https://myorbiit.com and https://sobrsafe.com.

1Source: American Addiction Centers

ABOUT SOBRsafe
Alcohol misuse is the fourth leading cause of preventable death in America, and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive and inefficient, unhygienic and unconnected. There has to be a better way.

Enter SOBRsafe™. Our advanced transdermal (touch-based) technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin – no breath, blood or urine sample is required. With a powerful backend data platform, SOBRsafe provides next generation, passive detection technology for the behavioral health, judicial and consumer markets, and for licensing and integration.

The SOBRsafe technology is commercially available for point-of-care screening (SOBRcheck) and continuous monitoring (SOBRsure). At SOBRsafe, we are creating a culture of prevention and support. To learn more, visit www.sobrsafe.com.

ABOUT Orbiit

Welcome to Orbiit, where innovation and compassion intersect to transform the landscape of addiction recovery. Our journey began with a simple yet powerful vision: to create a recovery program that not only addresses the complexities of addiction but also harnesses the power of cutting-edge technology to provide continuous, personalized support. Orbiit is a dynamic program that can be used as an after plan, probation fulfillment, accountability strategy and of course as a first line recovery guide.

PRESS CONTACT

Talia Rotenberg

[email protected]

310.339.3591

Safe Harbor Statement
Our prospects here at SOBRsafe are subject to uncertainties and risks. This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. The Company intends that such forward-looking statements be subject to the safe harbor provided by the foregoing Sections. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this presentation. The Company cannot predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements. The reader should consider statements that include the words “believes”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “projects”, “should”, or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. We caution readers not to place undue reliance upon any such forward-looking statements. The Company does not undertake to publicly update or revise forward-looking statements, whether because of new information, future events or otherwise. Additional information respecting factors that could materially affect the Company and its operations are contained in the Company’s filings with the SEC which can be found on the SEC’s website at www.sec.gov.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sobrsafe-and-orbiit-announce-partnership-to-enhance-alcohol-recovery-through-ai-and-wearable-technology-302380958.html

SOURCE SOBR Safe, Inc.

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025

PR Newswire


GAITHERSBURG, Md.
, Feb. 20, 2025 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 27, 2025. Details of the event and replay are as follows:

Conference call details:

Date:

February 27, 2025

Time:

8:30 a.m. U.S. ET

URL to register phone:



https://emportal.ink/3PsP11e

Dial-in number:

(800) 836-8184 (Domestic) or

(+1) (646) 357-8785 (International)

Webcast:

  ir.novavax.com/events

  • Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
  • Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
  • To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.

Replay details:

Date:

Available starting at 11:30 a.m. U.S. ET, February 27, 2025, until 11:59 p.m. U.S. ET, March 6, 2025

Dial-in number:

(888) 660-6345 (Domestic) or

(+1) (646) 517-4150 (International)

Passcode:

79349#

Webcast:


ir.novavax.com/events, until March 29, 2025

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax’s patented Matrix-M adjuvant to enhance the immune response. The Company’s portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax’s adjuvant is included in the University of Oxford and Serum Institute of India’s R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.

Contacts:

Investors

Luis Sanay, CFA
240-268-2022
[email protected]

Media

Giovanna Chandler

202-709-5563
[email protected]

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2024-financial-results-and-operational-highlights-on-february-27-2025-302381190.html

SOURCE Novavax, Inc.

El Pollo Loco Expands Popular Mango Habanero Flavor to Tostadas

Following the success of Mango Habanero Chicken Meals, the brand announces more sweet heat offerings 

COSTA MESA, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) — El Pollo Loco, the nation’s leading fire-grilled chicken restaurant, is building on the success of its recent Mango Habanero Chicken Meals by extending the flavor to its Tostadas. Starting February 20, fans can delight in the sweet and spicy flavors of the new Mango Habanero Double Tostadas.

The Mango Habanero Double Tostada comes in three delicious variations: classic Fire-Grilled Chicken, Baja shrimp or chicken and shrimp. The Mango Habanero Double Chicken Tostada features 65 grams of protein while the Mango Habanero Double Shrimp Tostada offers 40 grams. The vibrant Mango Habanero sauce enhances the flavors of the avocado, beans, rice, cheese, lettuce, sour cream, and salsa fresca, and it’s all served in a crispy tostada shell.

“Our customers have been loving the sweet heat of our Mango Habanero Chicken, so we wanted to give them more opportunities to enjoy this flavor innovation on additional menu items,” said Jill Adams, Chief Marketing Officer at El Pollo Loco. “Our tostadas provide the perfect backdrop for another deliciously swicy experience.”

Pricing for the Mango Habanero Double Tostadas starts at $11.29. Please note that prices and participation may vary by location. Mango Habanero Chicken Meals, Mango Habanero Tostadas and Mango Habanero Double Tostadas are available for a limited time at select El Pollo Loco locations.

To stay updated on the latest deals and offerings, download the Loco Rewards app and follow @elpolloloco on social media.

About El Pollo Loco

El Pollo Loco (Nasdaq: LOCO) is the nation’s leading fire-grilled chicken restaurant known for its craveable, flavorful, and better-for-you offerings. Recently voted as the #1 “Best Restaurant for Quick, Healthy Food” in USA TODAY’s 10 Best Readers’ Choice Awards, our menu features innovative meals with Mexican flavors made daily in our restaurants using quality ingredients. At El Pollo Loco, inclusivity is at the heart of our culture. Our community of over 4,000 employees reflects our commitment to creating a workplace where everyone has a seat at our table. Since 1980, El Pollo Loco has successfully expanded its presence, operating more than 495 company-owned and franchised restaurants across seven U.S. states: Arizona, California, Colorado, Nevada, Texas, Utah, and Louisiana. The company has also extended its footprint internationally, with eight licensed restaurant locations in the Philippines. For more information or to place an order, visit the Loco Rewards app or ElPolloLoco.com. Follow us on InstagramTikTokFacebook, or X.

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/535fbdcc-104b-4f1b-a8d0-ac9fe4773dc3



MEDIA CONTACT:
Glenda Vaquerano
The ID Agency
Account Director
[email protected]

Brittney Shaffer
El Pollo Loco
Director of Brand Communications
[email protected]

Fiverr Launches a Freelancer Equity Program to Give Direct Stake in the Business

The new program offers U.S. based top performing, eligible freelancers Fiverr’s shares

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) — Fiverr International Ltd. (NYSE: FVRR) launches a new Freelancer Equity Program that will grant shares to U.S. based top performing, eligible freelancers on the platform.

Coming at a time when freelancers are expected to represent half the U.S. workforce by 2027, the Freelancer Equity Program offers an opportunity to add supplementary financial value alongside individual earnings.

“Freelancers are the backbone of today’s economy and the heart of Fiverr’s success,” said Micha Kaufman, Founder & CEO of Fiverr. “With this initiative, they’re not just shaping the future of work—we’re actually giving them a piece of it, making Fiverr not just a platform for work, but a place where equity can also be earned.”

The program will reward U.S. based top performing, eligible freelancers on the platform with up to $10,000 in Fiverr shares. Eligible freelancers will be notified in the coming days about their eligibility to participate in the program, to receive equity grants over the course of four years based on annual eligibility requirements. The program is structured to encourage continued growth and excellence for those top freelancers, while at the same time serving as an aspiration for up and coming freelancers on the platform.

“This is something we’ve long wanted to offer, and after careful development and extensive work, we’ve created a program around how we can build success together with our talent,” added Kaufman. “This initiative demonstrates our commitment to innovation not just in technology, but in how we value and invest in our talent community.”

Learn more about Fiverr’s Freelancer Equity Program here.


Legal Disclaimer

Participation in Fiverr’s Freelancer Equity Program is subject to eligibility in accordance with the terms of the program. Fiverr reserves the right to cancel, amend or terminate the program at any time without prior notice. The program and each issuance of Fiverr’s shares are subject to applicable laws, including applicable U.S. securities laws.

Fiverr has filed a registration statement (including a prospectus) with the U.S. Securities and Exchange Commission (SEC) for the offering to which this communication relates. Before you enroll in the Fiverr Freelancer Equity Program, you should read the prospectus in that registration statement and other documents we filed with the SEC for more complete information about us and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Fiverr will send you the prospectus if you request it by emailing: [email protected].


About Fiverr

Fiverr’s mission is to change how the world creates and works together. We exist to democratize access to talent and to provide talent with access to opportunities so anyone can grow their business, brand, or dreams. From small businesses to Fortune 500, nearly 4 million customers worldwide worked with freelance talent on Fiverr in the past year, ensuring their workforces remain flexible, adaptive, and agile. With Fiverr Business Solutions, large companies can find the right talent and tools tailored to their needs to help them thrive and grow. On Fiverr, you can find over 700 types of skills, ranging from programming to 3D design, digital marketing to content creation, from video animation to architecture.

Join the movement that is shaping the future of work. Visit fiverr.com, and follow our blog and social channels on Instagram and Facebook.

Press Contacts:

Jenny Chang
Tommy Lee
[email protected]  

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5213cedf-5e8c-4ddc-891a-6dbe4409ffe9



Orchestra BioMed to Present at Upcoming Investor Conferences

NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple upcoming investor conferences.

Details on the Company’s presence at these conferences are shown below.


Presentations


TD Cowen 45



th



Annual Healthcare Conference


Format: Corporate Presentation
Date: March 3, 2025
Time: 2:30 PM ET
Webcast:https://wsw.com/webcast/cowen177/obio/2014707


Barclays 27



th



Annual Global Healthcare Conference


Format: Fireside Chat
Date: March 13, 2025
Time: 8:00 AM ET

Live audio webcasts of the TD Cowen presentation can be accessed through the Investors section of the Company’s website at https://investors.orchestrabiomed.com/news-events/events. An archived replay of the webcast will be available on the Company’s website for 90 days following the live event.

The Company will also be hosting 1×1 meetings with investors at the B. Riley Securities Precision Oncology & RadioPharma Conference on February 28, 2025.

About Orchestra BioMed

Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn .

References to Websites and Social Media Platforms

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

Investor Contact:

Jeremy Feffer
LifeSci Advisors
[email protected]

Media Contact:

Kelsey Kirk-Ellis
Orchestra BioMed
(484) 682-4892
[email protected]



Oxford Lane Capital Corp. Prices Public Offering of $165,000,000 7.95% Notes Due 2032

GREENWICH, Conn., Feb. 20, 2025 (GLOBE NEWSWIRE) — Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS: OXLCI) (the “Company”) today announced that it has priced an underwritten public offering of $165,000,000 in aggregate principal amount of 7.95% unsecured notes due 2032. The notes will mature on February 29, 2032, and may be redeemed in whole or in part at any time or from time to time at the Company’s option on or after February 28, 2030. The notes will bear interest at a rate of 7.95% per year payable quarterly on March 31, June 30, September 30, and December 31 of each year, commencing June 30, 2025.

The offering is expected to close on February 27, 2025, subject to customary closing conditions. The Company has granted the underwriters an option to purchase up to an additional $24,750,000 in aggregate principal amount of notes. The notes are expected to be listed on the NASDAQ Global Select Market and to trade thereon within 30 days of the original issue date under the trading symbol “OXLCG”.

The Company expects to use the net proceeds from this offering to acquire investments in accordance with its investment objective and strategies and for general working capital purposes.

Lucid Capital Markets, LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering, Clear Street LLC, InspereX LLC, Janney Montgomery Scott LLC and William Blair & Company, L.L.C. are acting as lead managers for the offering, and Ladenburg Thalmann & Co. Inc. is acting as co-manager for the offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities in this offering or any other securities nor will there be any sale of these securities or any other securities referred to in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

A shelf registration statement relating to these securities is on file with the Securities and Exchange Commission and is effective. The offering may be made only by means of a prospectus and a related prospectus supplement, copies of which may be obtained, when available, from the following investment banks: Lucid Capital Markets, LLC, 570 Lexington Ave, 40th Floor, New York, NY 10022 or by telephone number (646) 362-0256; Piper Sandler & Co., Attn: Debt Capital Markets, 1251 Avenue of the Americas, 6th Floor, New York, NY 10020 or by e-mailing [email protected]. The preliminary prospectus supplement, dated February 19, 2025, and accompanying prospectus, dated November 8, 2024, each of which has been filed with the Securities and Exchange Commission, contain a description of these matters and other important information about the Company and should be read carefully before investing. Investors are advised to carefully consider the investment objectives, risks and charges and expenses of the Company before investing.

About Oxford Lane Capital Corp.

Oxford Lane Capital Corp. is a publicly-traded registered closed-end management investment company principally investing in debt and equity tranches of collateralized loan obligation (“CLO”) vehicles. CLO investments may also include warehouse facilities, which are financing structures intended to aggregate loans that may be used to form the basis of a CLO vehicle.

Forward-Looking Statements

This press release contains forward-looking statements subject to the inherent uncertainties in predicting future results and conditions, including statements with regard to the anticipated use of the net proceeds of the Company’s offering of the Notes. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements. These statements are not guarantees of future performance, conditions or results and involve a number of risks and uncertainties. Certain factors could cause actual results and conditions to differ materially from those projected in these forward-looking statements. These factors are identified from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect subsequent events, except as may be required by law.

Contact:

Bruce Rubin
203-983-5280



Conduit Progresses Phase II of its AI Initiative with Sarborg

  • Collaboration reinforces Conduit’s commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug development
  • Sarborg delivers a prototype AI-product to Conduit’s Management team

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2025 (GLOBE NEWSWIRE) — Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), is pleased to announce the completion of the initial milestones in Phase II of its strategic collaboration with AI and Cybernetics company, Sarborg Limited. Further to the Company’s previous announcement regarding the successful completion of Phase I, this next phase focuses on the prototype development of personalized dashboards, a critical tool designed to provide Conduit’s key personnel with real-time access to data related to deliverables, research and development oversight, and drug discovery.

This pivotal stage delivers a prototype AI product to Conduit’s management team, providing user dashboards and interface mock-ups to enable real-time evaluation of key deliverables. Whilst these dashboards are still in development, they will undergo continuous reassessment and improvement to enhance efficiency and data analysis. The early development of the platform allows for further refinement and enhancements, incorporating management expertise and input to maximize efficiency.

Conduit’s collaboration with Sarborg demonstrates its commitment to addressing longstanding challenges in the pharmaceutical sector, including reducing human error in critical decision-making processes such as clinical development and asset identification. By integrating Sarborg’s algorithmic AI and cybernetics technology, Conduit aims to improve efficiency, lower costs, and accelerate timelines, ultimately optimizing the drug development cycle while maintaining a competitive edge.

Conduit is excited by the unique software progress to-date and remains dedicated to adopting forward-thinking solutions to stay at the forefront of innovation in its industry, reducing reliance on traditional, labour-intensive methods, and harnessing the power of AI-driven technology to maximise clinical decision-making efficiency alongside its Phase II clinical programs in auto-immune disorders.

About Conduit Pharmaceuticals

Conduit is a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. David Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit’s future results of operations and financial position, Conduit’s business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks  as identified in filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit’s control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.

Investors & Media:

[email protected]



Pacira to Report 2024 Financial Results on Thursday February 27, 2025

PARSIPPANY, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2024 financial results after the close of the U.S. markets on Thursday February 27, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.

For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.



Investor Contact:

Pacira BioSciences, Inc.
Christian Pedetti, (973) 254-4387
[email protected]

Aterian Issues Letter to Shareholders

SUMMIT, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) — Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”), a technology-enabled consumer products company, today issued the following letter to shareholders from Arturo Rodriguez, Chief Executive Officer, and the Company’s Board of Directors.

Dear Fellow Shareholders:

While this is our first time writing to you directly, you are always at the forefront of our minds.

Over the past 18 months, our team has undertaken a comprehensive reassessment of nearly every facet of Aterian’s business model as part of our turnaround strategy. This deep evaluation of our brand portfolio, marketing strategies, inventory management, marketplace operations, supply chain, and overall fixed costs laid the foundation for the strategic initiatives we have implemented. By successfully executing these changes, we have focused, simplified, and stabilized the Company, positioning Aterian to drive long-term shareholder value.

Although there is still work to be done, we believe that 2025 marks the start of a new and promising chapter for Aterian as we pivot from stabilizing our operations towards sustainable growth.


2024: A Year of Achievement

2024 was a year of achievement as we delivered on many of our key objectives which we announced in late 2023. We streamlined our product portfolio to six highly regarded foundational brands—Squatty Potty, hOmeLabs, PurSteam, Mueller Living, Photo Paper Direct, and Healing Solutions—that deliver quality, affordable products to consumers. We also simplified our go-to-market and marketing strategies, improved efficiencies in our marketplace account structures and our supply chain and transitioned from an internally developed tech platform to a best-in-class third-party model, thereby increasing our efficiency, nimbleness, and cost savings. Additionally, we improved our working capital profile by completing our inventory rightsizing and renegotiating and extending our credit facility.

In late 2024, we launched several new products under our PurSteam and Mueller Living brands, marking an exciting return to our product development efforts. Organic product launches remain an important component of our growth strategy, and we expect to continue these efforts throughout 2025, with a focus on the second half of the year.

We also continue to deliver on our commitment to implementing an omnichannel sales approach to reach new consumers and remain competitive in the ever-evolving e-commerce landscape. In the fourth quarter of 2024, we began selling products from our hOmeLabs, PurSteam, and Mueller Living brands on Target+, the invitation-only online marketplace of Target Corporation, while expanding product offerings of Squatty Potty on Target+. This complements our established marketplace strength on Amazon.com, Walmart.com, and Mercado Libre in Mexico, as well as our direct-to-consumer websites. We also recently refreshed our PurSteam and Mueller Living websites, modernizing them to match the recent updates of those brands.


Our Efforts are Yielding Tangible Results

Our progress was evident in our third quarter 2024 year to date financial results. When compared to the same nine-month period in 2023, we generated significant improvements in gross margin and contribution margin, and narrowed our net loss by $56.3 million, or 84%.

We also reported positive adjusted EBITDA for both the second and third quarters of 2024.

At September 30, 2024, our cash flow from operations was $2.2 million, a $10.6 million improvement from the same period in 2023, our credit facility balance declined by $4.4 million from December 31, 2023, and we had cash on hand of $16.1 million.


Fourth Quarter 2024 Preliminary Results

This momentum carried into the final quarter of the year. For the fourth quarter of 2024, we now expect to report net revenue between $24.2 million and $25.0 million which is at the higher end of our previous guidance of $22.5 million to $25.5 million. As previously disclosed, we continue to expect that this level of revenue will produce approximately breakeven adjusted EBITDA.

We expect that our cash position at December 31, 2024 will improve to approximately $18 million from $16.1 million at September 30, 2024, while our credit facility balance is expected to increase slightly from $6.7 million at September 30, 2024 to approximately $6.9 million at December 31, 2024.


Full Year 2025: From Stability to Growth

Looking ahead to 2025, we are confident that Aterian will evolve into a growth company, driven by our omnichannel expansion initiatives, organic product launches, and a commitment to prudent capital allocation strategies. In comparison to 2024, we expect to produce higher revenue, along with continuing improvements in operating efficiencies and adjusted EBITDA. More importantly, we believe that our efforts to date have placed us firmly on the path to producing these results on a sustainable basis.

We believe we have taken a conservative approach in our expectations for 2025 by considering both the potential impact of increased tariffs on Chinese imports, and to a lesser extent, those from Canada, as well as the proactive measures we would implement to mitigate their effects. Our primary strategy to offset these tariffs would be price adjustments on select products, supplemented by additional cost-management initiatives, if deemed necessary. As trade policies evolve, we will continue to monitor developments and adjust our responses, as needed.

We are continuing our efforts to identify product sourcing alternatives outside of China, wherever possible, in response to the current uncertainty of U.S. trade policies. As we navigate these challenges, we are fortunate to be supported by a strong balance sheet that provides us with the flexibility to adapt as needed while remaining focused on long-term growth and profitability.

We look forward to providing additional clarity on our plans and outlook for 2025 in connection with our fourth quarter and full year financial results conference call scheduled for mid-March, and keeping you apprised of material developments.

Looking ahead, the strength of our brands, the influence and accessibility provided by our marketplace relationships, and our passionate, talented and tenacious people will allow us to deliver on our mission to position Aterian to deliver sustainable, long-term shareholder value. We remain grateful for the continuing support of our shareholders. We hope this is the beginning of more frequent communications as we share in the excitement of Aterian’s bright future.

Best regards,

Arturo Rodriguez
Chief Executive Officer

About Aterian, Inc.

Aterian, Inc. (Nasdaq: ATER) is a technology-enabled consumer products company that builds and acquires leading e-commerce brands with top selling consumer products, in multiple categories, including home and kitchen appliances, health and wellness and air quality devices. The Company sells across the world’s largest online marketplaces with a focus on Amazon,Walmart and Target in the U.S. and on its own direct to consumer websites. Our primary brands include Squatty Potty, hOmeLabs, Mueller Living, PurSteam, Healing Solutions and Photo Paper Direct. To learn more about Aterian and its brands, visit aterian.io

Forward Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, regarding our expectations for growth in 2025, including our omnichannel expansion initiatives, organic product launches and our capital allocation strategies. These forward-looking statements are based on management’s current expectations and beliefs and are subject to a number of risks and uncertainties and other factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to our ability to continue as a going concern, our ability to meet financial covenants with our lenders, our ability to maintain and to grow market share in existing and new product categories; our ability to continue to profitably sell the SKUs we operate; our ability to create operating leverage and efficiency when integrating companies that we acquire, including through the use of our team’s expertise, the economies of scale of our supply chain and automation driven by our platform; those related to our ability to grow internationally and through the launch of products under our brands and the acquisition of additional brands; those related to consumer demand, our cash flows, financial condition, forecasting and revenue growth rate; our supply chain including sourcing, manufacturing, warehousing and fulfillment; our ability to manage expenses, working capital and capital expenditures efficiently; our business model and our technology platform; our ability to disrupt the consumer products industry; our ability to generate profitability and stockholder value; international tariffs and trade measures; inventory management, product liability claims, recalls or other safety and regulatory concerns; reliance on third party online marketplaces; seasonal and quarterly variations in our revenue; acquisitions of other companies and technologies and our ability to integrate such companies and technologies with our business; our ability to continue to access debt and equity capital (including on terms advantageous to the Company) and the extent of our leverage; and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), all of which you may obtain for free on the SEC’s website at www.sec.gov.

Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.


Contact:
 
The Equity Group

Devin Sullivan

Managing Director
[email protected]

Conor Rodriguez
Associate
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fac8af25-1eb0-4a9b-b114-ed58c424cb02